RPF1

Across TCGA pan-cancer cohorts, RPF1 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of RPF1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where RPF1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types RPF1 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

CCRCC, COAD, and LSCC are the cancer types where RPF1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPF1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	+0.383	<.001	12	view →
COAD	Male	III,IV	+0.853	<.001	11	view →
LSCC	Male	II,III,IV	+0.607	<.001	8	view →
LUAD	Male	II,III,IV	+0.303	<.001	8	view →
HNSC	All	III,IV	+0.165	.004	6	view →
PDAC	Female	All	−0.569	.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

RPF1–CCRCC

Open the CCRCC breakdown →